Drug Pricing
The proposed CMS innovation center's $2 drug list model will not address the barriers to newer generics getting on Part D formularies and plans may have little incentive to participate in the demo, an industry group said.
The US FTC and FDA both received letters from the Senate but with different messaging. One commends for achieved findings and requests a new investigation and another scalds for not doing the assigned job.
Japan has started to charge patients a portion of the difference between the reimbursement price of the generic and non-generic product if they insist on the latter without a supporting recommendation from the prescribing physician, in a policy designed to further drive generic use.
In a closely anticipated US Senate Committee hearing, Novo’s CEO was grilled by US senator Bernie Sanders and others on the high price of Ozempic and Wegovy in the country.
Pharmacy benefit manager sues Federal Trade Commission, claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.
After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape. Generics Bulletin looks at the latest trends.
After UK apixaban prices started to creep up in July, the latest WaveData figures show several different presentations of the generic increasing their average price by multiples in August.
In a frank acknowledgement of Sandoz’s position in the US small-molecule generics market, the company’s North America president Keren Haruvi has indicated that the firm is “not looking to be a leader in the generics space” and is still suffering from a lack of investment made in its pipeline during the period several years ago when it was looking to sell the oral solids business.
Glenmark Pharmaceuticals has agreed a $25m payout in the US to resolve its alleged liability under the False Claims Act linked to historical price-fixing allegations.
The latest figures on uptake for rivals to Humira in the US show adalimumab biosimilars beginning to capture significant market share from the originator, AbbVie’s Humira, after an initially slow start in 2023.
July’s UK generic pricing figures from WaveData show captopril tablets rocketing up in price, while aripiprazole prices continue to plummet.
Boehringer Ingelheim is partnering with GoodRx in the US to offer a version of its Humira biosimilar at a 92% discount to the brand’s list price. Generics Bulletin spoke with Chris Marsh, Boehringer’s senior vice president of value and access, about the initiative.
The latest UK generic pricing information from WaveData shows multiple products doubling or even trebling their average prices in June.
Almost a year after launching Celltrion’s Yuflyma rival to Humira in the US, Tom Nusbickel, chief commercial officer of Celltrion USA, reflects on experiences in the market so far and key launches on the horizon, in an exclusive interview with Generics Bulletin.
With a fresh pricing deal on the horizon, Medicines for Ireland chair and Teva country head Paul Neill talks to Generics Bulletin about the need for the Irish off-patent industry to have “a true seat at the table” and secure an agreement with the country’s government that better reflects the specificities of the generics and biosimilars market.
Global biosimilars player Pfizer is calling for a more sustainable approach to the market to ensure its long-term viability. In the second part of an exclusive interview, Barry Chester, the firm’s global commercial lead for supportive care oncology, tells Generics Bulletin where the company sees room for improvement.
Pfizer is one of the leading players in the global biosimilars market. Barry Chester, the firm’s global commercial lead for supportive care oncology, talks to Generics Bulletin about how the business fits into the firm’s wider interests, in the first part of an exclusive interview.
Pregabalin topped our table of Biggest Risers in May, in another month of multiple treble-digit-percentage average price increases for the UK generics market.
With UK shortages and price rises making headlines in early 2024, April’s generic pricing data suggested an easing of pricing increases, according to the latest figures from WaveData.
Despite receiving mixed opinions on the Medicare Part D final rule, CMS sees support from the off-patent group AAM, which said that the new policy will have an “immediate impact” on cost reduction and increased access to biosimilars.